Shares of Halozyme Therapeutics Inc. (NASDAQ:HALO) traded down 4.9% during trading on Tuesday . The stock traded as low as $9.75 and last traded at $9.80, with a volume of 580,697 shares changing hands. The stock had previously closed at $10.30.

Several analysts have commented on the company. Canaccord Genuity reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, May 10th. Wells Fargo & Co. reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, May 10th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $15.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, June 9th. Finally, Jefferies Group reiterated a “sell” rating and set a $6.75 target price on shares of Halozyme Therapeutics in a research report on Tuesday, May 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. Halozyme Therapeutics presently has a consensus rating of “Buy” and an average target price of $15.68.

The stock has a 50-day moving average of $8.98 and a 200-day moving average of $9.31. The firm’s market cap is $1.28 billion.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.04. The firm earned $42.50 million during the quarter, compared to analyst estimates of $29.65 million. The firm’s revenue for the quarter was up 127.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.12) earnings per share. On average, equities analysts forecast that Halozyme Therapeutics Inc. will post ($1.03) earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the company. Nationwide Fund Advisors increased its position in Halozyme Therapeutics by 2.3% in the fourth quarter. Nationwide Fund Advisors now owns 69,817 shares of the biopharmaceutical company’s stock worth $1,210,000 after buying an additional 1,563 shares during the period. California Public Employees Retirement System increased its position in Halozyme Therapeutics by 10.2% in the fourth quarter. California Public Employees Retirement System now owns 255,600 shares of the biopharmaceutical company’s stock worth $4,430,000 after buying an additional 23,600 shares during the period. Finally, New York State Common Retirement Fund increased its position in Halozyme Therapeutics by 5.4% in the fourth quarter. New York State Common Retirement Fund now owns 372,785 shares of the biopharmaceutical company’s stock worth $6,460,000 after buying an additional 18,940 shares during the period.

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.